Trial Profile
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Tisagenlecleucel (Primary) ; Tocilizumab
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ELARA
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 12 Apr 2024 Last checked against European Clinical Trials Database record.
- 29 Feb 2024 Results from ELARA and ZUMA-5, comparing efficacy and safety outcomes in r/r FL using matching-adjusted indirect comparison methodspublished in the Leukemia and Lymphoma
- 12 Dec 2023 Results (As of March 29, 2023, n=97 )assessing longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition